Update IPO News Of Cardiovascular biotech Gemphire Therapeutics

Update IPO News Of Cardiovascular biotech Gemphire Therapeutics

Gemphire Therapeutics, a cardiovascular biotech developing therapies for the treatment of dyslipidemia, filed on Monday with the SEC to raise up to $60 million in an initial public offering.

The Northville, MI-based company was founded in 2014. Gemphire Therapeutics filed confidentially on September 11, 2015. Jefferies and Cowen & Company are the joint bookrunners on the deal. No pricing terms were disclosed.

Share on Google Plus

About Jessica Hornberger

This is a short description in the author block about the author. You edit it by entering text in the "Biographical Info" field in the user admin panel.